Deferoxamine

What it is used for

Deferoxamine mesylate for injection is an iron-chelating agent indicated: As an adjunct to standard measures for the treatment of acute iron intoxication. For the treatment of transfusional iron overload in patients with chronic anemia. Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder).

Acute Iron Intoxication Deferoxamine mesylate for injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. Chronic Iron Overload Deferoxamine mesylate for injection is indicated for the treatment of transfusional iron overload in patients with chronic anemia. Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder).

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Hypersensitivity Reactions
• Auditory and Ocular Toxicity
• Renal Toxicity
• Respiratory Toxicity
• Growth Suppression
• Serious Infections
• Cardiac Dysfunction with Concomitant Use of Vitamin C
• Risks of Deferoxamine Mesylate for Injection Treatment in Patients with Aluminum Overload
• Effects on Ability to Drive and Use Machines

Who should not take it

Deferoxamine Mesylate for Injection is contraindicated in patients with:

• A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients. Reactions have included anaphylaxis.
• Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney.

Storing it

Storage and Handling

STORE AT: 20 ºC to 25 °C ( 68 ºF to 77 °F).

The container closure is not made with natural rubber latex.

2 dosage and administration

The dosage (based on body weight in mg/kg/day), rates of administration, and mode of administration for both adults and pediatric patients are individually determined and adapted during the course of therapy based on the severity of the patient's iron overload. The minimum daily dose of Deferoxamine Mesylate for Injection is 20 mg/kg/day for both adults and pediatric patients. The maximum daily dose is 40 mg/kg/day for pediatric patients and 60 mg/kg/day for adults.